Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the company has sold its 10 millionth DreamWear CPAP mask and interchangeable cushion. As part of the award-winning Dream Family, DreamWear is the only mask frame that accommodates multiple cushions, places the hose on top of the head, and is designed to prevent red marks, discomfort and irritation on the nose bridge. Philips is committed to its continued effort to improve the lives of patients living with sleep apnea by developing solutions that put the patient’s experience and comfort first. Sleep apnea is estimated to affect more than 100 million of people [1]. In the U.S. alone, it’s estimated that 22 million Americans suffer from sleep apnea [2]. In an effort to improve the quality of life for those living with this chronic condition, Philips designed its DreamWear mask system – a radical departure from traditional CPAP mask technology that features an open-faced frame and hose-on-top design – that provides patients with an unparalleled level of comfort and freedom of movement and helps to prevent red marks, discomfort and nose bridge irritation. Designed to more efficiently meet provider needs for mask change flexibility, DreamWear is the only modular mask frame system on the market that works interchangeably with nasal, pillow and full-face cushions. With the ability to work with all three cushion types, DreamWear fits over 95 percent of sleep apnea patients. “The invention of the DreamWear mask was not just an incremental improvement on existing CPAP mask designs, but a generational leap forward in terms of comfort and usability,” said John Frank, Business Leader of Sleep & Respiratory Care at Philips. “Selling 10 million masks and cushions in just three years is a testament to the popularity of the patient-centric approach to design in health care, in addition to a proof point in the effectiveness of our innovative line of masks. This is just the latest example of Philips’ commitment to providing effective therapy options for sleep apnea patients, working toward our company-wide goal of improving three billion lives a year by 2025.” Philips Respironics is the number one choice sleep therapy brand by U.S. sleep physicians for CPAP and masks. Philips entire portfolio of sleep solutions – including the recently announced expansion of consumer sleep solutions featuring the award-winning SmartSleep Deep sleep headband and Snoring relief band – is rooted in nearly 40 years of deep clinical expertise in sleep technology and, today, we continue to pave the way to make good sleep accessible for everyone by connecting daily living to sleep health. For more on Philips' advanced solutions for sleep and respiratory care, follow @PhilipsResp or visit www.philips.com.
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips' health technology portfolio generated 2017 sales of EUR 17.8 billion and employs approximately 77,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.